Dr. Venkata Mahidhar Yenugonda

Dr. Venkata Yenugonda, the Chief Operating Officer at T&T Scientific, is a Completed Tenure Track Professor and Scientist, holding Ph.D. in Nanomedicinal Chemistry from one of the world's earliest groups in gene delivery and gene therapy fields. Dr. Yenugonda is an accomplished LNP drug discovery and delivery leader with broad experience across the science, technologies, business, and management sectors. Moreover, Dr. Yenugonda is a proven and highly motivated on hypothesis-driven application of state-of-the-art Lipid Nanoparticle (LNP) drug products platform technologies and automation to deliver innovative solutions to complex scientific problems across multiple drug project phases, including lead discovery, lead optimization, and IND enabling studies. He has also proven his track record with experiences he had in business development activities including academic/pharma/CRO collaborations, evaluation and engaging in licensing and partnership opportunities. Dr. Yenugonda has a deep understanding of the field and working knowledge in the drug formulation development process, including nonclinical pharmacology, CMC, drug substance (API), as well as drug products, and IND application frameworks. He has contributed and held 3 Issued US patents, 2 PCT, and one provisional patent; and his scientifical contribution of his is one that stands out by 30 accepted peer-reviewed manuscripts in high-impact journals. Prior to joining T&T, he was an Associate Professor and Director at Saint John's Cancer Institute in Los Angeles.


Contact Operational Unit

Areas of Expertise and Interests

  • High Impact LNP Delivery Research, Development, Manufacturing Optimization and Technologies: More than 14+ years in academia with additional industry collaboration experience in support of multidisciplinary LNP drug discovery and delivery projects, with a track record of delivering best in class liposome drug products. Extensive experience in discovering novel cationic and ionizable lipids for nucleic acid delivery. Experienced in formulation optimization aspects, transfection, and dosing regimen. Experienced in rigorous QC process and ADME/PK characterization of final liposome drug product including drug substance (payload), lipids, nonlipid components of the liposomes (Cholesterol, PEG), Nanoliposome inactive ingredients (e.g., buffer components). Experienced in applying STED (Spreading through and reaching appropriate cells in the target tissue, transduction efficiency) parameters to optimize payload pharmacodynamics.

  • High Impact Nonclinical and Clinical Pharmacology Research: Comprehensive understanding and capability of the interplay between nonclinical pharmacology (ADME, DMPK, PK/PD, DDI risks) and toxicology methodologies to support early and late-stage lipid-based drug developmental programs. Extensive experience interfacing with, and providing scientific guidance to, and manage both US domestic and international CRO partners for non-GLP and GLP pharmacology and safety studies. Proficient in design and execution of biodistribution and bioanalytical assay methods for biology specific PD and target occupancy studies.

  • High Impact Clinical Drug Development Research: As a Center for Professional Innovation & Education (CfPIE) Pharmaceutical and biopharmaceutical Certified Professional, I have familiar with regulations, best practices, and regulatory guidelines in general (ICH, FDA, EMA) and expert knowledge of those related to nonclinical pharmaceutical product development. In addition, I have completed certification course for Principles of Clinical Pharmacology from the NIH office of Clinical Research. As a member of Saint John’s Cancer Institute ’s translational and clinical advisory board, I have reviewed investigator initiated and IRB clinical protocols related to investigator’s Brochure document, involving strategic planning, and initiated corrective actions as needed.

Inventions and Patents - Intellectual Properties

  1. Yenugonda, V. M.; Chaudhuri, A.; Rama Mukherjee. Process for the synthesis of glycomimicking cationic amphiphiles. US Granted Patent (US 8,278,483 B2) October 2, 2012.
  2. Yenugonda, V. M.; Milton L. Brown. Fluorescent CDK inhibitors for the treatment of cancer. US Granted Patent (US 2011/0269178 A1), November 3, 2011.
  3. Milton L. Brown; Mikell A. Paige.; Yingxian Xiao.; Kenneth J. Kellar, Yenugonda, V. M. Phenyl substituted nicotinic ligands and methods of use thereof. US Granted Patent (US 2014/0323461 A1) October 30, 2012.
  4. Yenugonda, V.M.; Kesari, S. Small Molecule Autophagy Inducers for the treatment of Cancer and Neurodegenerative Diseases. PCT/US2020/029580 filed on April 24, 2020.
  5. Yenugonda, V.M.; Kesari, S. New Temozolomide analogs for better CNS outcome for CNS Cancers. PCT/US2021/043773 filed on July 29, 2021
  6. Yenugonda, V.M. Cell cycle inhibitors for treating cancer. US Provisional Patent application in process US Provisional Patent application 63/210,795, Filed date, June 15, 2021
  7. Yenugonda, V.M. Repurposed nanotherapeutics for treating pediatric high-grade glioma. US Provisional Patent application in process
  8. Yenugonda, V.M. Targeting cell cycle proteins in treating neurogenerative diseases. US Provisional Patent application in process

Peer-Reviewed Manuscripts and Invited Talk

  1. Bhargav, P.; Jayaraman, R.; Babu,S.; Nanjundappa,M.; Waters,A.; Morris-Stiff, G.; Yenugonda, V. M.* OncoDynamiX: A novel mechanism-based integrated technology platform for the selection of cell lines for screening compounds in cancer drug discovery Patterns (Cell Press) Under Review *Corresponding Author

  2. Waters, ; Tomimatsu,N.; Babic,I.; Nurmemmedov, E.; Allnutt, A.; Quan, Y.; Natsuko Nomura, N.; Burma, S.; Kesari, S.; Yenugonda, V.M* Novel Temozolomide Analogs with Improved Brain Exposure: Design, Synthesis and Biological Evaluation in Glioblastoma Multiforme ACS Chem Neurosci (Communicating soon) *Corresponding Author
  3. Waters, ; Khoury, Lea el ; Sasmal, S.; Mobley, D.L.; Lanceta, L.; Dougherty, S.M.; Imbert-Fernandez. Y.; Yenugonda, V.M. * New class of merioline-3 on Basal like Triple Negative Breast Cancer Proliferation Manuscript Under Preparation *Corresponding Author
  4. Sasaki, T.; Zou, L.; Katagi, H.; Water , A.; Hashizume, R.; * Yenugonda, V.M. * Novel Brain Penetrant potent pan- CDK2 inhibitor for Diffuse Intrinsic Pontine Glioma Manuscript Under Preparation * Equal Corresponding Author

  5. Joshi, ; Mukherjee, A.; Waters, A.; Betageri, G.V.; Yenugonda, V.M. * Development of First Generation ALK Inhibitor Liposomal Formulations for Enhancing Anti-Cancer Activity International Journal of Molecular Sciences*Corresponding Author

  6. Naeem, ; Harish, V.; Coste, S.; Parasido, E. M.; Choudhry, M. U.; Kromer, L. F.; Ihemelandu, C.; Petricoin, E. F.; Pierobon, M.; Noon, M. S.; Yenugonda, V. M.; Avantaggiati, M.; Kupfer, G.; Fricke, S.; Rodriguez, O.; Albanese, C., Regulation of chemosensitivity in human medulloblastoma cells by p53 and the PI3 Kinase signaling pathway. Mol Cancer Res 2021.PMID: 34635507

  7. Allnutt, B.; Waters, A. K.; Kesari, S.; Yenugonda, V. M *Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease. ACS Chem Neurosci 2020, 11 (9), 1218-1230. PMID: 32286796*Corresponding Author

  8. Her, G.; Babic, I.; Yenugonda, V. M.; Kesari, S.; Nurmemmedov, E., Cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changes. Biotechniques 2020, 68 (4), 180-184.PMID: 32040335
  9. Cheltsov, ; Nomura, N.; Yenugonda, V. M.; Roper, J.; Mukthavaram, R.; Jiang, P.; Her, N. G.; Babic, I.; Kesari, S.; Nurmemmedov, E., Allosteric inhibitor of beta-catenin selectively targets oncogenic Wnt signaling in colon cancer. Sci Rep 2020, 10 (1), 8096. PMID: 32415084

  10. Mukherjee, ; Waters, A. K.; Kalyan, P.; Achrol, A.S.; Kesari, S.; Yenugonda, V. M*. Lipid-Polymer hybrid nanoparticles as a next generation drug delivery platform : state of the art, emerging technologies and perspectives. Int J Nanomedicine 2019, 19, 1937-1952.PMID: 30936695 *Corresponding Author

  11. Yadavalli, S.; Yenugonda, V.M.; Kesari, S. Repurposed Drugs in Treating Glioblastoma Multiforme: Clinical Trials Update. Cancer J.2019, 25, 139-146. PMID: 30896537

  12. Levin, E. D.; Rezvani, A. H.; Wells, C.; Slade, S.; Yenugonda, V. M.; Liu, Y.; Brown, M. L.; Xiao, Y.; Kellar, K. J., alpha4beta2 Nicotinic receptor desensitizing compounds can decrease self-administration of cocaine and methamphetamine in rats. Eur J Pharmacol 2019, 845,1-7

  13. Rezvani, H.; Slade, S.; Wells, C.; Yenugonda, V. M.; Liu, Y.; Brown, M. L.; Xiao, Y.; Kellar, K. J.; Levin, E. D. Differential efficacies of the nicotinic alpha4betadesensitizing agents in reducing nicotine self-administration in female rats. Psychopharmacology (Berl) 2017, 2517-2523. PMID. 28555315

  14. Yenugonda, M.; Nomura, N.; Kouznetsova,V.; Tsigelny, I.; Fogal, V.; Yang, J.; Nurmemmedov, E.; Kesari, S.; and Babic, I. A Novel Small Molecule Inhibitor of Mitochondrial p32. J Transl Med, 2017, 15, 210. PMID. 29047383

  15. Waye, ; Naeem, A.; Choudhry, M.U.; Parasido, E.; Tricoli, L.; Sivakumar, A.; Mikhaiel, J.P.; Yenugonda, V.; Rodriguez, O.C.; Karam, S.D.; Rood, B.R.; Avantaggiati, M.L and Albanese.C. The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human human medulloblastoma cells, Aging (Albany NY). 2015, 7, 854-68, PMID: 26540407.

  16. Dixon, M.; Woodrick, J.; Gupta, S.; Karmahapatra, S.K.; Devito, S.; Vasudevan, S.; Dakshanamurthy, S.; Adhikari, S.; Yenugonda, M.; Roy R. Naturally occurring polyphenol morin hydrate, inhibits enzymatic activity of N- methylpurine DNA glycosylase, a DNA repair enzyme with various roles in human disease Bioorg Med Chem. 2015, 23, 1102-11. PMID: 25650313.

  17. Kong, S.; Song, Jun-ke.; Yenugonda, V.M.; Zhang, Li.; Shuo, T.; Kong, Y.; Du, Guan-hua.; Paige, M.; Brown, M.L. Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95 Mol Pharm. 2015, 12, 393- 402, PMID: 25533629.

  18. Ringer, L.; Sirajuddin,P.; Tricoli, L.; Waye, ; Choudhry, M.;Parasido, E.; Sivakumar, A.; Heckler, M.; Naeem, A.; Abdelgawad, I.; Liu, X.; Feldman, A.; Lee, R.; Wu, Chin-Lee.; Yenugonda, V.M; Kallakury, B.; Dritschilo, A.; JohnLynch, J.; Schlegel, R.; Rodriguez, O.; Pestell, R.; Avantaggiati, M and Albanese., C. The Induction of the p53 Tumor Suppressor Protein Bridges the Apoptotic and Autophagic Signaling Pathways to Regulate Cell Death in Prostate Cancer Cells, Oncotarget. 2014, 5, 10678-91, PMID: 25296977.

  19. Yenugonda, M.; Xiao,Y.; Levin,E.D.; Rezvani, A.H.; Tran,T.; Al-Muhtasib, N.; Sahibzada, N.; Xie, T.; Wells, C.; Slade, S.; Johnson, J. E.; Dakshanamurthy, S.; Kong, H. S.; Tomita,Y.; Liu,Y.; Paige,M.; Kellar,K.J.; Brown,M.L. Design,

  20. Synthesis and Discovery of Picomolar Selective alpha4beta2 Nicotinic Acetylcholine Receptor Ligands. J. Med. Chem. 2013 56(21): 8404-21. PMID: 24047231.

  21. Mukherjee, ; Waters, A. K.; Babic, I.; Nurmemmedov, E.; Glassy, M. C.; Kesari, S.; Yenugonda, V. M. * Antibody drug conjugates: Progress, pitfalls, and promises. Hum Antibodies 2019, 27, 53-62.PMID: 30223393 Future Med Chem 2018, 10 (12), 1399-1403.PMID. 29779411

  22. Tao, ; Li, S.; Ichim, T. E.; Yang, J.; Riordan, N.; Yenugonda, V.M; Babic, I.; Kesari, S., Cellular immunotherapy of cancer: an overview and future directions Immunotherapy 2017, 9 , 589-606. PMID: 28595516.

  23. Liu, ; Richardson, J.; Tran, T.; Al-Muhtasib, N.; Xie, T.; Yenugonda, V. M.; Sexton, H. G.; Rezvani, A.H.; Levin, D.; Sahibzada, N.; Kellar, K. J.; Brown, M. L.; Xiao, Y.; Paige, M. Chemistry and pharmacological studies of 3- alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats. J. Med. Chem. 2013, 56, 3000-11. PMID: 23540678.

  24. Levin, E.D.; Sexton, H.G.; Gordon, K.; Gordon, C.J.; Xiao, Y.; Kellar, K.J.; Yenugonda, V.M.; Liu, Y.; White, M.P.; Paige, M.; Brown, M.L.; Rezvani,A.H. Effects of the sazetidine-a family of compounds on the body temperature in wildtype, nicotinic receptor beta2(-/-) and alpha7(-/-) Eur. J. Pharmacol. 2013, 718, 167-172. PMID: 24036108.

  25. Yenugonda, V. M.; Kong, Y.; Deb, T. B.; Yang, Y.; Riggins, R. B.; Brown, M. L. Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells. Cancer Biol. Ther. 2012, 13, 925-934. PMID: 22785207.

  26. Sirajuddin, P.; Das, S.; Ringer, L.; Rodriguez, O.; Sivakumar, A.; Lee, Y.C.; Uren, A.; Fricke, S.T.; Rood, B.; Ozcan, A.; Wang, S.S.; Karam, S.; Yenugonda, V. M.; Salinas, P.; Petricoin E 3rd.; Pishvaian, M.; Lisanti,M.P.; Wang, Y.; Schlegel, ; Moasser, B.; Albanese, C. Quantifying the CDK inhibitor VMY-1-103’S activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. Cell Cycle. 2012, 20, 3801-9 PMID: 22983062.

  27. Yenugonda, M.; Deb, T. B.; Grindrod, S. C.; Dakshanamurthy, S.; Yang, Y.; Paige, M.; Brown, M. L. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg. Med. Chem. 2011, 19, 2714-2725. PMID: 21440449.

  28. Ringer, ; Sirajuddin, P.; Heckler, M.; Ghosh, A.; Suprynowicz, F.; Yenugonda, V. M.; Brown, M. L.; Toretsky, J. A.; Uren, A.; Lee, Y.; MacDonald, T. J.; Rodriguez, O.; Glazer, R. I.; Schlegel, R.; Albanese, C. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol. Ther. 2011, 12, 818-826. PMID: 21885916.

  29. Ringer, ; Sirajuddin, P.; Yenugonda, V. M.; Ghosh, A.; Divito, K.; Trabosh, V.; Patel, Y.; Brophy, A.; Grindrod, S.; Lisanti, M. P.; Rosenthal, D.; Brown, M. L.; Avantaggiati, M. L.; Rodriguez, O.; Albanese, C. VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol. Ther. 2010, 10, 320-325. PMID: 20574155.

  30. Srinivas, ; Karmali, P. P.; Pramanik, D.; Garu, A.; Yenugonda, V. M.; Majeti, B. K.; Ramakrishna, S.; Srinivas, G.; Chaudhuri, A. Cationic amphiphile with shikimic acid headgroup shows more systemic promise than its mannosyl analogue as DNA vaccine carrier in dendritic cell based genetic immunization. J. Med. Chem. 2010, 53, 1387-1391. PMID: 20050668.

  31. Mukthavaram, R.; Marepally, S.; Yenugonda, V. M.; Vegi, G. N.; Sistla, R.; Chaudhuri, A. Cationic glycolipids with cyclic and open galactose head groups for the selective targeting of genes to mouse liver. Biomaterials. 2009, 30, 2369-2384. PMID: 19157538.

  32. Hwang, S. H.; Rait, A.; Pirollo, K. F.; Zhou, Q.; Yenugonda, V. M.; Chinigo, G. M.; Brown, L.; Chang, E. H. Tumor- targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol. Cancer Ther. 2008, 7, 559-568. PMID: 18347143.

  33. Yenugonda, M.; Rajesh, M.; Madhavendra, S. S.; Chaudhuri, A. Distance of hydroxyl functionality from the quaternized center influence DNA binding and in vitro gene delivery efficacies of cationic lipids with hydroxyalkyl headgroups. J. Med. Chem. 2004, 47, 5721-5728. PMID: 15509171.

  34. Yenugonda, M.; Rajesh, M.; Chaudhuri, A. Spacer-arm modulated gene delivery efficacy of novel cationic glycolipids: design, synthesis, and in vitro transfection biology. J. Med. Chem. 2004, 47, 3938-3948. PMID: 15267233.

  35. Banerjee, R.; Yenugonda, V. M.; Chaudhuri, A.; Gopal, V.; Rao, N. M. Design, synthesis, and transfection biology of novel cationic glycolipids for use in liposomal gene J. Med. Chem. 2001, 44, 4176-4185. PMID: 11708919.

  36. Wagle, N.; Juarez, T.; Carrillo, J.; Heng, A.; Gill, J.; Min Nguyen, M.;Truong, J.; Boucher,N.; Archer, A.; Nguyen,H.; Nomura,N.; Yenugonda, M.; Allnutt, A.; Barkhoudarian, G.; Kelly, D.; Kesari, S. Phase I open-label, single-center, dose escalation study (NCT02434525) of pulsatile Afatinib in patients with brain cancer. Society for Neuro- Oncology (SNO) 26th Annual Meeting. 2021, Boston

  37. Waters, A.; Khoury, Lea el ; Sasmal, S.; Mobley, D.L.; Lanceta, L.; Dougherty, S.M.; Imbert-Fernandez. Y.; Yenugonda, V.M. * Developing small molecule targeted therapies for basal-like triple negative breast cancer 47th Annual Meeting of Korean Cancer Association and the 7th International Cancer Conference, *Corresponding Author

  38. Waters, ; Tomimatsu,N.; Babic,I.; Nurmemmedov, E.; Allnutt, A.; Quan, Y.; Natsuko Nomura, N.; Burma, S.; Kesari, S.; Yenugonda, V.M. * Novel temozolomide analogs to improve anti tumor efficacy and overcome resistant in glioblastoma multiforme. Society for         Neuro-Oncology (SNO) 25th Annual Meeting. 2020, Virtual.*Corresponding Author

  39. Waters, ; Yadavalli, S.; Marzese, D.; Orry, A.; Senugupta, S.; Quan,Y.; Nomura, N.; Allnutt, A.; Kesari, S.; Yenugonda, V.M * Small molecule targeting regulated cell death pathways in treating triple negative breast cancer, SABCS, San Antonio, TX, 2019 .*Corresponding Author

  40. Ariana Waters, A.; Nurmammadov, E.; Nomura, N.; Babic,I.; Kesari, S.; Yenugonda, V.M.* Small molecule autophagy activators in growth inhibition of glioblastoma Society for Neuro-Oncology (SNO) 24th Annual Meeting. 2019, Scottsdale, AZ .*Corresponding Author

  41. Mukthavaram, R; Jiang, ; Yenugonda, V.M.; Pingle, S.; Nomura, N.; Babic, I.; Kesari , S. Antibody-Drug Conjugates as Novel Approach to Treat Glioblastoma 2016 ABTA National Patient and Family Conference, Rosemont, IL.

  42. Nomura, ; Nurmammadov,E.; Ravula,S.; Kouznetsova, V.; Tsigelny, I.; Yenugonda,V.M.; Kesari, S and Babic, I. Small molecule inhibitors of C1qBP for therapeutic intervention in glioma. Society for Neuro-Oncology (SNO) 21st Annual Meeting. 2016, Scottsdale, AZ.

  43. Yenugonda, M.; Xiao, Y.; Levin, E.D.; Rezvani, A.H.; Tran, T.; Al-Muhtasib, N.; Sahibzada, N.; Xie, T.; Wells, C.;

  44. Slade, S.; Johnson, J. E.; Dakshanamurthy, S.; Kong, H. S.; Tomita,Y.; Liu,Y.; Paige, M.; Kellar, K.J.; Brown, M. L. Design, Synthesis and Pharmacological Evaluation of a series of Novel Picomolar Selective alpha4beta2 Nicotinic Acetylcholine Receptor Ligands, Gordon Research Conference meeting, 2013, New London, NH.

  45. Babic, ; Yenugonda, V. M.; Kesari, S.; Nurmemmedov, E. Wnt pathway: a hallmark of drug discovery challenge.

  46. Curing Alzheimer’s using AI and Knowledge, Live webinar LinkedIn, Wisecube AI [2021]

  47. Novel Chemical Technologies to Overcome Challenges in Brain Research, Triangular Talk, Agora Math Circle [2021]

  48. In Silico Accelerating Therapeutics in Medicine: An Effective Paradigm Shift in Drug Discovery and Development SJCI’s Grand Rounds [2021]

  49. Novel Targeted Therapeutics for Triple Negative Breast Cancer, 3rd international conference on Pharma R&D [2021]

  50. Novel Temozolomide Analogs to improve anti-tumor efficacy and overcome resistance in Glioblastoma, Neuro- Oncology Meeting [2021]

  51. The need for smart approaches in CNS drug discovery, why drugs have failed and what can be done to improve outcomes, SJCI’s Grand Rounds [2021]

  52. Development of novel CDK2/1 inhibitors for treatment of pediatric brain cancer [2019] Neuroscience Seminar Series, Saint John’s Foundation, Santa Monica, California, USA

  53. Novel Drug Development for Central Nervous System (CNS) Diseases [2018] Brain Trust Committee meeting, Saint John’s Foundation, Santa Monica, California, USA

  54. Precision Drug Development for Prostate Cancer (Pca) Therapy [2018] Urology Research Meeting, John Wayne Cancer Institute, Santa Monica, California, USA

  55. Optimizing Therapeutic Nanomedicine for Brain Cancer [2017] Indian Society of Neuro-Oncology Conference, Bangalore, India

  56. Discovery and development of a novel highly selective a4�2 nicotinic acetylcholine receptor partial agonist as promising new medication for smoking cessation [2014]. Reddy's Laboratories Ltd, Hyderabad

  57. A systematic approach to the development of fluorescent CDK small molecule inhibitor for treatment of triple negative breast cancer [2013]. Biochemistry and Molecular Biology Department, Howard University School of Medicine, Washington

  58. Design, synthesis and characterization of picomolar selective a4�2 nicotinic acetylcholine receptor inhibitors [2012]. 244th American Chemical Society National Meeting held at Philadelphia, PA.

  59. Discovery of a fluorescent cyclin-dependent kinase inhibitor with potent antiproliferative activity in human breast cancer cells [2010]. 240th American Chemical Society National Meeting

  60. Design, synthesis of novel imageable therapeutic small molecules as inhibitors of cyclin-dependent kinases (CDKs) [2010]. Piramal Life Sciences Limited, Mumbai,

  61. Discovery of a novel structural class of CDK small molecule inhibitors for cancer therapy [2010] Sai Advantium Pharma Ltd, Hyderabad-74 , India

  62. Wagle, N.; Juarez, T.; Carrillo, J.; Heng, A.; Gill, J.; Min Nguyen, M.;Truong, J.; Boucher,N.; Archer, A.; Nguyen,H.; Nomura,N.; Yenugonda, M.; Allnutt, A.; Barkhoudarian, G.; Kelly, D.; Kesari, S. Phase I open-label, single-center, dose escalation study (NCT02434525) of pulsatile Afatinib in patients with brain cancer. Society for Neuro- Oncology (SNO) 26th Annual Meeting. 2021, Boston

  63. Waters, A.; Khoury, Lea el ; Sasmal, S.; Mobley, D.L.; Lanceta, L.; Dougherty, S.M.; Imbert-Fernandez. Y.; Yenugonda, V.M. * Developing small molecule targeted therapies for basal-like triple negative breast cancer 47th Annual Meeting of Korean Cancer Association and the 7th International Cancer Conference, *Corresponding Author

  64. Waters, ; Tomimatsu,N.; Babic,I.; Nurmemmedov, E.; Allnutt, A.; Quan, Y.; Natsuko Nomura, N.; Burma, S.; Kesari, S.; Yenugonda, V.M. * Novel temozolomide analogs to improve anti tumor efficacy and overcome resistant in glioblastoma multiforme. Society for         Neuro-Oncology (SNO) 25th Annual Meeting. 2020, Virtual.*Corresponding Author

  65. Waters, ; Yadavalli, S.; Marzese, D.; Orry, A.; Senugupta, S.; Quan,Y.; Nomura, N.; Allnutt, A.; Kesari, S.; Yenugonda, V.M * Small molecule targeting regulated cell death pathways in treating triple negative breast cancer, SABCS, San Antonio, TX, 2019 .*Corresponding Author

  66. Ariana Waters, A.; Nurmammadov, E.; Nomura, N.; Babic,I.; Kesari, S.; Yenugonda, V.M.* Small molecule autophagy activators in growth inhibition of glioblastoma Society for Neuro-Oncology (SNO) 24th Annual Meeting. 2019, Scottsdale, AZ .*Corresponding Author

  67. Mukthavaram, R; Jiang, ; Yenugonda, V.M.; Pingle, S.; Nomura, N.; Babic, I.; Kesari , S. Antibody-Drug Conjugates as Novel Approach to Treat Glioblastoma 2016 ABTA National Patient and Family Conference, Rosemont, IL.

  68. Nomura, ; Nurmammadov,E.; Ravula,S.; Kouznetsova, V.; Tsigelny, I.; Yenugonda,V.M.; Kesari, S and Babic, I. Small molecule inhibitors of C1qBP for therapeutic intervention in glioma. Society for Neuro-Oncology (SNO) 21st Annual Meeting. 2016, Scottsdale, AZ.Yenugonda, M.; Xiao, Y.; Levin, E.D.; Rezvani, A.H.; Tran, T.; Al-Muhtasib, N.; Sahibzada, N.; Xie, T.; Wells, C.;

  69. Slade, S.; Johnson, J. E.; Dakshanamurthy, S.; Kong, H. S.; Tomita,Y.; Liu,Y.; Paige, M.; Kellar, K.J.; Brown, M. L. Design, Synthesis and Pharmacological Evaluation of a series of Novel Picomolar Selective alpha4beta2 Nicotinic Acetylcholine Receptor Ligands, Gordon Research Conference meeting, 2013, New London, NH.

  70. Levin,E.D.; Slade,S.; Wells,C.; Briggs, A.; Zhang, G.; Rezvani, A.H.; Xiao,Y.; Kellar, K.J.; Yenugonda, V.M.; Paige, M.; Brown, M.L. The a4�2 nicotinic desensitizing agent VMY-2-109 significantly decreases nicotine self administration in Neuroscience Meeting (545.26/MM10),2013, San Diego, CA.

  71. Kong, S.; Song, J.; Yenugonda, V. M.; Zhang, L.; Tian, S.; Kong, Y.; Xiao, Y.; Kellar, K. J.; Du, G.; Paige, M.; Brown, L.; Bioavailability and Pharmacokinetic Studies of VMY-2-95·2HCl, a Potent and Selective Nicotinic α4β2 Receptor Ligand. AAPS Annual Meeting and Exposition, 2013, San Antonio, TX.

  72. Yenugonda, M.; Deb, T. B.; Brown, M. L. Development of Novel CDK1 Small Molecule ‘VMY-1-103’ for Inhibition of Triple Negative Breast Cancer Cell Growth. Sixth Annual Frontiers at the Chemistry-Biology Interface Symposium (FCBIS), 2013, College Park, Maryland.

  73. Liu, Y.; Richardson, J.; Tran, T.; Al-Muhtasib, N.; Xie, T.; Sexton, H.G.; Rezvani, A.H.; Levin, E.D.; Yenugonda, V.M.; Sahibzada, N.; Kellar, K.J.; Paige, M.; Xiao, Y.; Brown, M.L Desensitizers of the α4β2 Nicotinic Acetylcholine Receptors with Reduced Agonist Properties for the Treatment of Alcohol 43 rd National Organic Chemistry Symposium, 2013, Washington, Seatle.

  74. Ringer, L.; Sirajuddin, P.; Yenugonda, V. M.; Brown, M.L.; Rodriguez, O.; Albanese, C. Role of p53 in cdk inhibitor VMY-1-103-induced apoptosis in prostate cancer (abstract # 3052) In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72 (8 Suppl): doi:1538-7445.AM2012-3052.

  75. Sirajuddin, ; Das, S.; Ringer, L.; Salinas, P.; Rodriguez, O.; Brow, M.L.; Yenugonda. V.M.; Moasser, B.; Albanese,

  76. LC-MS/MS detection of the dansyl-modified biologically active CDK inhibitor VMY-1-103 using an in vivo model system (abstract # 4774) In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl): doi: 10.1158/1538-7445.AM.

  77. Yenugonda, M.; xiao, Y.; Levin, E. D.; Rezvani, A.H.; Tran, T.; Al-Muhtasib, N.; Wells, C.; Slade, S.; Johnson, J. E.; Kong, H. K.; Dakshanamurthy, S.; Tomita, Y.; Liu, Y.; Paige, M.; Kellar, K.J.; Brown, M. L. Design, Synthesis and

  78. Characterization of Picomolar Selective a4�2 Nicotinic Acetylcholine Receptor Inhibitors. 244th Americal Chemical Society National Meeting (Scimix #33), 2012 held at Philadelphia, PA

  79. Slade, ; Wells, C.; Burke, D.; Johnson, J. E.; Rezvani, A. H.; Kellar, K. J.; Xiao, Y.; Yenugonda, V.M.; Paige, M.; Brown, M.; Levin, E.D. The a4�2 nicotinic desensitizing agent VMY-2-95 decreases nicotine self-administration in rats. Neuroscience Meeting (455.05/Q1), 2012, New Orleans, LA.

  80. Xiao, Y.; Tuan, E.; Sahibzada, N.; Tran, T.; Al-Muhtasib, N.; Yasuda, R.P.; Liu, Y.; Yenugonda, V.M.; Paige, M.; Brown, ; Kellar, K. J. Comparison of pharmacological properties of human vs rat α4β2 and α3β4 nicotinic acetylcholine receptors stably expressed in HEK293 cells. Neuroscience Meeting (640.15/C45), 2012 , New Orleans, LA.

  81. Ringer, L.; Heckler, M.; Ghosh, A.K.; Sirajuddin, P.; Yenugonda, V. M.; Brown, M.L.; Rodriguez, O.; Albanese, C. CDK Inhibitor VMY-1-103 Causes Cell Cycle Arrest and Apoptosis in Cancer Cell The International Conference “Georgetown Lombardi Research Days”, 2011 held at Georgetown University, Washington DC, USA.

  82. Ringer, L.; Heckler, M.; Ghosh, A.K.; Sirajuddin, P.; Yenugonda, V. M.; Brown, M.L.; Rodriguez, O.; Albanese, C. CDK Inhibitor VMY-1-103 Causes Cell Cycle Arrest and Apoptosis in Cancer Cell The International Conference “Cell Cycle Regulators/Inhibitors and Cancer”, 2011 held at Vienna, Austria.

  83. Yenugonda, V. M.; Deb, T.B.; Grindrod, S.; Yang, Y.; Brown, M.L. Discovery, imaging, and effects of fluorescent CDK inhibitors on human breast cancer cells Published in the 238 th Americal Chemical Society National Meeting (Abstract # 291), 2009, Washington

  84. Yenugonda, V. M.; Stoica, B.; Byrnes, K.B.; Cheema, A.; Faden, A.L.; Brown, M.L. Design and synthesis of novel fluorescent conjugated roscovitine analogs as tools for understanding neuronal apoptosis Published in the 238 th Americal Chemical Society National Meeting (Abstract # 275), 2009, Washington

  85. Yenugonda, V.M.; Kong, Y.; Deb, T.B.; Yang, Y.; Grindrod, S.; Brown, M.L. Discovery of a boronic acid analog of resveratrol as a potent inhibitor of human breast cancer cell proliferation Published in the 238 th Americal Chemical Society National Meeting (Abstract # 277), 2009, Washington DC

  86. Hwang, S.H.; Rait, A.; Pirollo, K.F.; Zhou, Q.; Yenugonda, V. M.; Brown, M.L.; Chang, E.H. Targeted delivery via nanocapsules improves the efficacy of small molecules currently in use as anticancer therapeutics? Published in 4 th Annual symposium of the American Academy of Nanomedicine held at the Maryland

  87. Yenugonda, V. M.; Suy, S.; Stoica, B.; Faden, A.I.; Brown, M.L. Discovery and synthesis of a new class of potent fluorescent roscovitine analogs, Published in the 236 th Americal Chemical Society National Meeting (Abstract # 371), 2008, Philadelphia,

  88. Hwang, S.H.; Rait, A.; Pirollo, K. F.; Zhou, Q.; Yenugonda, V.M.; Brown, M.L.; Chang E.H. Enhanced Efficacy of Anticancer Small Molecules via tumor-targeting via Tumor-Targeting Nanodelivery System, Lombardi Annual meeting 2008, Lombardi Cancer Center, Washington DC

  89. Banerjee, ; Yenugonda, V.M.; Chaudhuri, A.; Gopal, V.; Rao, N.M. Design, Synthesis, and Transfection Biology of Novel Cationic Glycolipids for Use in Liposomal Gene Delivery Published in the Proceedings of the 7th National Bioorganic Symposium (page 52), 2001, Guru Nanak Dev University, Amritsar, India.